S-1/A: CG Oncology Eyes Nasdaq Debut with $16-$18 IPO, Advancing Bladder Cancer Therapy

CG Oncology, a late-stage biopharmaceutical company, is set to launch its IPO on the Nasdaq, aiming to raise capital for its bladder cancer therapeutic, cretostimogene.

Summary

• CG Oncology, Inc., a clinical-stage biopharmaceutical company, is planning an initial public offering (IPO) to list its common stock on the Nasdaq Global Select Market under the symbol CGON.
• The company is offering 11,800,000 shares of common stock with an anticipated initial public offering price between $16.00 and $18.00 per share.
• The offering is contingent upon Nasdaq approval.
• CG Oncology is focused on developing and commercializing cretostimogene, a bladder-sparing therapeutic for bladder cancer patients.
• Cretostimogene is currently in Phase 3 clinical trials for patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) therapy.
• Topline data from the Phase 3 trial is expected by the end of 2024.
• The company is also evaluating cretostimogene in combination with pembrolizumab in a Phase 2 clinical trial.
• CG Oncology intends to use the net proceeds from the IPO, along with existing capital, to fund research and development of cretostimogene and for general corporate purposes.
• The company estimates net proceeds from the offering to be approximately $181.1 million, or $209.0 million if underwriters exercise their over-allotment option in full.
• CG Oncology believes these funds will be sufficient to fund operations into the second half of 2027.
• The company reported net losses of $12.8 million and $35.4 million for 2021 and 2022, respectively, and anticipates continued losses as it progresses its clinical trials and seeks regulatory approval.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company has promising clinical data and is pursuing a significant market opportunity, it also faces financial challenges and competition. The IPO is a positive step, but the company's future success is uncertain.

Positives

• Cretostimogene has shown promising clinical utility and tolerability in trials.
• The company has a strong management team and is backed by healthcare-specific investors.
• Cretostimogene has received fast track designation from the FDA.
• The company has a clear strategy for development and commercialization of cretostimogene.
• The company has a CMC Advisory Board providing differentiated expertise in production and potential commercialization of cretostimogene.

Negatives

• The company has a limited operating history and has incurred significant operating losses.
• The company depends entirely on the success of cretostimogene, which is its only product candidate.
• The company relies on third parties for clinical trials and manufacturing.
• The company faces significant competition in the biopharmaceutical industry.
• The company may find it difficult to enroll patients in its clinical trials.

Risks

• The company may never generate any revenue or become profitable.
• The company will require substantial additional capital to finance its operations.
• Clinical trials may not be successful, and regulatory approval may not be obtained.
• Use of cretostimogene could be associated with adverse side effects.
• The company may be subject to product liability lawsuits.
• The company's information technology systems may fail or suffer security incidents.
• The company's business is subject to risks arising from pandemics and epidemic diseases.

Future Outlook

The company expects to continue to incur significant expenses and operating losses in the foreseeable future as it continues its development of, seeks regulatory approval for, and potentially commercializes cretostimogene and potentially seeks to discover and develop additional product candidates.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on oncology and specifically bladder cancer. The company faces competition from established pharmaceutical companies and other biotechnology firms developing treatments for NMIBC and MIBC.

Comparison to Industry Standards

• The company's lead product candidate, cretostimogene, will compete with existing therapies and new therapies that may become available in the future, including surgery, radiation, and drug therapy, such as chemotherapy, BCG, hormone therapy, biologic therapy, such as monoclonal and bispecific antibodies, antibody-drug conjugates, radiopharmaceuticals, immunotherapy, cell-based therapy, and targeted therapy, or a combination of any such methods, either approved or under development.
• The company will compete with numerous companies that have commercialized or are developing treatments for NMIBC, including Bristol Meyers Squibb, enGene Inc., Gilead Sciences, Inc., Hoffman-La Roche AG (Roche), ImmunityBio Inc., Johnson & Johnson Inc., Merck, Protara Therapeutics, Inc., Pfizer, Inc. and UroGen Pharma, Inc.
• The company's competitors have developed, are developing or may develop products, product candidates and processes competitive with cretostimogene.

Management Changes

Related Party Transactions

• Simone Song is a Founder and Senior Partner at ORI Capital and a member of the company's board of directors.
• Victor Tong, Jr. is a Managing Director at Decheng and a member of the company's board of directors.
• Brian Liu, M.D. is a Managing Director at Longitude Capital Management and a member of the company's board of directors.
• Jue Pu, a former member of the company's board of directors, is an affiliate of Lepu Holdings Limited.
• Osamu Nakanishi, a former member of the company's board of directors, is an affiliate of Kissei.

Stakeholder Impact

• Shareholders will be diluted by the issuance of new shares in the IPO.
• Employees may benefit from the company's growth and success.
• Patients may benefit from the development of new bladder cancer therapies.
• Suppliers and creditors may benefit from the company's increased financial stability.

Next Steps

• Complete the ongoing BOND-003 Phase 3 trial of cretostimogene as monotherapy in high-risk BCG-unresponsive NMIBC and pursue FDA approval.
• Expand the development of cretostimogene monotherapy as a potential backbone therapy across NMIBC indications.
• Continue to evaluate cretostimogene in combination with other therapies, such as CPIs, to potentially further enhance its clinical utility across various stages of bladder cancer.
• Build operational capabilities to successfully commercialize cretostimogene.
• Leverage CMC expertise and relationships to scale commercialization efforts.

Key Dates

Keywords

cretostimogene, bladder cancer, NMIBC, clinical trial, biopharmaceutical, FDA, IPO, oncology, BCG, therapy